In another study, Lu et al., 2016 used an inhibitor of its interaction with NRF2, CPUY192018, and observed that activated NRF2 acted as a protective factor upon exposure to DSS, decreasing CRC risk [33]. This evidence concerns the gene NFE2L2 and colorectal carcinoma.